FINWIRES · TerminalLIVE
FINWIRES

Everest Medicines Unit Grants Kidney Disease Development, Commercialization License

By

Everest Medicines (HKG:1952) unit Everest Medicines (Singapore) entered into an exclusive agreement to provide an exclusive worldwide license to Travere Therapeutics to develop and commercialize civorebrutinib, according to a Tuesday Hong Kong bourse filing.

Travere Therapeutics can commercialize the drug globally except in Greater China and certain countries in East and Southeast Asia.

Everest Medicines (Singapore) will receive an upfront payment of $112.5 million under the deal and up to $1.03 billion in development, regulatory, and commercial milestone payments across a maximum of five indications, alongside tiered royalties.

Civorebrutinib has the potential to serve as a pipeline-in-a-product across multiple immune-mediated kidney diseases.

Related Articles

Asia

Fujikon Industrial Forecasts Narrower Full-Year Loss

Fujikon Industrial (HKG:0927) expects an attributable loss of between HK$23.3 million and HK$29 million for the year ended March 31, compared with HK$36.1 million a year prior, according to a Tuesday Hong Kong bourse filing.The headset maker attributed the forecast to the absence of a cash payment to a customer, as well as an expected decline in general and administrative expenses.

$HKG:0927
Asia

Agile Group Logs 650 Million Yuan in May Pre-Sale Value

Agile Group (HKG:3383) recorded a pre-sold value of around 650 million yuan in May, with a gross floor area (GFA) of 58,000 square meters, according to a Tuesday Hong Kong bourse filing.The property firm's average selling price for the month was 11,193 yuan per square meter.For the five months ended May 31, pre-sold value and GFA reached roughly 2.98 billion yuan and 281,000 square meters, respectively, with an average selling price of 10,634 yuan per square meter.

$HKG:3383
Asia

E. Bon Warns of Wider Full-Year Loss

E. Bon Holdings (HKG:0599) expects a pre-tax loss of between HK$23 million and HK$25 million for the year ended March 31, compared with HK$11.9 million a year prior, according to a Tuesday Hong Kong bourse filing.The architectural hardware and household equipment wholesaler attributed the forecast to a non-cash impact from the revaluation of certain properties, as well as a lower revenue and gross profit.

$HKG:0599